sunesis
pharmaceuticals
announces
presentation
preclinical
data
symposium
molecular
targets
cancer
therapeutics
south
san
francisco
globe
newswire
sunesis
pharmaceuticals
nasdaq
snss
today
announced
poster
presentation
symposium
molecular
targets
cancer
therapeutics
held
october
virtual
format
details
poster
presentation
follows
date
time
october
et
abstract
title
inhibitor
shows
synergy
standard
cancer
therapies
solid
tumor
hematologic
cancer
models
session
name
molecular
targeted
agents
publication
number
full
abstract
viewed
poster
made
available
sunesis
website
time
presentation
sunesis
pharmaceuticals
sunesis
biopharmaceutical
company
developing
novel
targeted
inhibitors
treatment
hematologic
solid
cancers
sunesis
built
experienced
drug
development
organization
committed
improving
lives
people
cancer
company
focused
advancing
novel
kinase
inhibitor
pipeline
including
inhibitor
studies
vecabrutinib
completed
phase
trial
patients
advanced
b
cell
malignancies
additional
information
sunesis
please
visit
sunesis
logos
trademarks
sunesis
pharmaceuticals
inc
statements
press
release
contains
statements
including
statements
related
sunesis
continued
development
potential
kinase
inhibitor
pipeline
including
therapeutic
potential
vecabrutinib
words
expect
look
forward
similar
expressions
intended
identify
statements
statements
based
upon
sunesis
current
expectations
statements
involve
risks
uncertainties
sunesis
actual
results
timing
events
could
differ
materially
anticipated
statements
result
risks
uncertainties
risk
factors
discussed
risk
factors
sunesis
quarterly
report
form
quarter
ended
june
sunesis
filings
securities
exchange
commission
sunesis
expressly
disclaims
obligation
undertaking
release
publicly
updates
revisions
statements
contained
herein
reflect
change
sunesis
expectations
regard
thereto
change
events
conditions
circumstances
statements
based
